What is the role of the EVI1 protein in AML?

Updated 26 Nov 2018
Lead researcher - Dr Stefan Meyer, University of Manchester
Investigations into EVI1 interaction dynamics for therapeutic targeting
Amount awarded: £231,620
Award start date: 01 May 2016
Award duration: 3 years (36 months)

A gene called EVI1 is known to play a role in the development of acute myeloid leukaemia (AML).

When the activity of EVI1 is high, this makes AML even harder to treat. Researchers still do not fully understand how EVI1 causes AML to develop, and how it enables the leukaemia to resist treatment.

The EVI1 gene produces the EVI1 protein, which can react with other proteins in the cells, and can also control the activity of other genes. Dr Stefan Meyer and his team at the University of Manchester have previously found that changes to the EVI1 protein can alter its function, and now want to explore this further.

By gaining a better understanding of the EVI1 protein and how it works, the team aim to identify possible new targets for treatment in AML.